Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2022-09-01 Declaration of Voting R…
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Number of voting rights as of August 31, 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal publication dated September 01, 2022, titled 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS'. It explicitly references French regulatory articles (Code de Commerce and AMF regulations) and provides the share capital and total voting rights as of August 31, 2022. This type of regular, mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing, often related to capital structure updates or mandatory periodic reporting. While it relates to capital, it is a specific regulatory disclosure about the total count, not a financing event (CAP) or a general share transaction (POS). It fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory disclosure that doesn't match the other specialized codes, although it is highly specific. Given the options, RNS is the most appropriate fallback for mandatory, non-financial-statement regulatory updates that aren't director dealings or major shareholding changes (MRQ, which usually reports a change crossing a threshold, not the monthly total). However, since it is a mandatory disclosure about the total number of shares and voting rights, it is a specific regulatory announcement. Let's re-evaluate the options. It is not a DIV, SHA, or POS. It is a mandatory regulatory disclosure. RNS is the best fit as a general regulatory filing.
2022-09-01 English
Nombre de droits de vote au 31 août 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short, formal announcement dated September 1, 2022, titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF Regulation) and provides a snapshot of the share capital and voting rights as of August 31, 2022. This type of mandatory periodic disclosure regarding share structure and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning capital structure changes or status. Given the options, it is a specific regulatory filing that doesn't match the defined categories like Director's Dealing (DIRS), Major Shareholding (MRQ), or Share Issue (SHA). Since it is a mandatory regulatory disclosure that doesn't fit the other specific codes, the most appropriate fallback is Regulatory Filings (RNS), as it is a general regulatory announcement.
2022-09-01 French
Nicox : Participation à des conférences financières et scientifiques au troisième trimestre 2022
Regulatory Filings Classification · 95% confidence The document is a press release titled "Nicox : Participation à des conférences financières et scientifiques au troisième trimestre 2022" (Nicox: Participation in financial and scientific conferences in the third quarter of 2022). It details the management's schedule for attending upcoming financial conferences (like H.C. Wainwright events) and scientific meetings (like AAO 2022) during Q3 2022. This type of announcement, informing investors about management's planned engagement schedule at industry events, is best classified as an Investor Presentation (IP) or a general announcement. Since it is not a full report (10-K, IR), a specific financial result (ER), or a management discussion (MDA), and it focuses on future investor/scientific engagement, it aligns most closely with materials presented to investors. However, given the options, this is a specific announcement about management's planned activities and presentations, which often accompanies or precedes investor outreach. It is not a formal Investor Presentation (IP) document itself, but an announcement *about* participation. It is also not a standard Regulatory Filing (RNS) as it is a specific corporate event update. The closest fit among the provided codes for an announcement detailing management's schedule for investor/scientific engagement is often grouped with Investor Presentation materials or treated as a general announcement. Given the focus on management participation in investor conferences, it is a form of investor relations communication. Since there isn't a specific 'Investor Conference Schedule Announcement' code, and it's not a formal presentation (IP), the most appropriate general category for non-standard, forward-looking corporate updates that don't fit elsewhere is RNS, but since it is clearly about management's investor outreach schedule, it is often categorized alongside Investor Presentations (IP) or Management Reports (MDA). Because it is an announcement detailing *where* management will be presenting/meeting investors, it is a form of investor relations communication. I will classify this as an Investor Presentation (IP) as it relates directly to management's planned interactions and presentations to the investment community, even though it is an announcement *of* those plans, rather than the presentation itself. If the document were shorter and just said 'presentation attached', RPA would be better. Since it details multiple future events, IP is a reasonable fit for investor-focused scheduling information.
2022-08-03 French
Nicox to Participate in Financial and Scientific Events in Q3 2022
Report Publication Announcement Classification · 99% confidence The document is titled "Press Release" and announces the company's participation schedule for upcoming financial and scientific events (conferences) during Q3 2022. It lists specific dates, locations, and the executives who will be presenting or available for meetings. This type of announcement, detailing future corporate engagement schedules, does not fit the definitions for formal financial reports (10-K, IR, ER), management discussions (MDA), or specific regulatory filings. It is a general corporate communication about investor relations activities. Since it is not a specific report type, and it is a general announcement, the most appropriate classification is Regulatory Filings (RNS) as a catch-all for non-standard corporate announcements, although it strongly relates to investor relations activities.
2022-08-03 English
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET NOMBRE TOTAL DE DROITS DE VOTE AU 1ER AOUT 2022
Share Issue/Capital Change Classification · 95% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a snapshot of the share capital and voting rights as of July 31, 2022. This type of periodic disclosure regarding share structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning capital structure changes or status. Since there is no specific code for 'Monthly Share Capital Publication', and it is a mandatory regulatory filing that doesn't fit other specific categories like Director's Dealing (DIRS) or Share Issue (SHA) which usually imply a transaction, the most appropriate fallback category is Regulatory Filings (RNS).
2022-08-01 French
NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND TOTAL NUMBER OF VOTING RIGHTS AS OF AUGUST 1, 2022
Share Issue/Capital Change Classification · 95% confidence The document is titled 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' and explicitly references French regulatory articles (Code de Commerce and AMF Règlement général). It provides a snapshot of the total number of shares and voting rights as of a specific date (July 31, 2022). This content directly relates to tracking ownership structure and voting power, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it is a formal, periodic disclosure of voting rights structure, even if it's not the final result of a specific vote. It is a specific regulatory disclosure related to voting rights.
2022-08-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.